Omeros Corporation (Nasdaq: OMER) today announced the publication of a peer-reviewed manuscript in Blood Advances, a journal ...
A research team has outlined how synthetic biology can accelerate discoveries in plant–microbe interactions, offering ...
Claseprubart is an investigational, clinical-stage, potent monoclonal antibody engineered to selectively target the classical pathway by inhibiting only the active form of the C1s protein, a ...
Have a question for Heidi Borst or our other editors? Ask here for a chance to be featured in a story. Thank you for submitting your question. Keep reading Forbes Advisor for the chance to see the ...
BYU-Pathway Worldwide students in Lagos, Nigeria gather in March 2024. Enrollment in Nigeria surged from 6,603 students in 2023 to 11,724 in 2024. With higher education experiencing unprecedented ...
--- Ruxoprubart (NM8074) met all clinical endpoints, offering a safe, differentiated treatment for Paroxysmal Nocturnal Hemoglobinuria (PNH). Paroxysmal Nocturnal Hemoglobinuria (PNH) is a rare ...
Elevated Plasma MBL Levels Are Associated With Risk of Future Venous Thromboembolism: The HUNT Study
MBL (mannose-binding lectin), a pattern recognition molecule circulating in complex with MASPs (MBL-associated serine proteases), activates the lectin complement pathway and facilitates thrombin ...
5 Semmelweis University, Department of Internal Medicine and Haematology, Budapest, Hungary 6 Semmelweis University-Eötvös Loránd Research Network (Office for Supported Research Groups), Research ...
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) is advancing its potential best-in-class complement inhibitor drug DNTH103 for a wide variety of autoimmune disorders. In particular, it is looking at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback